MedTrace Logo

TME Neoadjuvant Breast Registry

NCT02596724 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2015-11-05

No results posted yet for this study

Summary

Prospective observational registry that links results of the genomic and other molecular testing to treatment response and survival measures in patients who have been diagnosed with breast cancer and who are targeted for neo-adjuvant therapy. Analysis includes how tests impact treatment decisions and outcomes.

Conditions

Interventions

OTHER

Genomic and/or molecular testing of blood or tissue

Genomic and/or molecular testing of blood or tissue

Sponsors & Collaborators

  • Targeted Medical Education

    lead OTHER

Principal Investigators

  • Pat Whitworth, M.D. · Nashville Breast Center

  • Peter Beitsch, M.D. · Dallas Surgical Group

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-07-31
Completion
2022-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02596724 on ClinicalTrials.gov